Basic aspects of vasorelaxant and bronchodilating peptides in clinical use: Urodilatin (INN: Ularitide), VIP, and PACAP

Annals of the New York Academy of Sciences

Volumn 805, Issue , 1996, Pages 443-463

  Meyer, Markus ^a   Flüge, Thomas ^a   Kruhøffer, Mogens ^a   Forssmann, Wolf Georg ^a  

^a IPF PHARMACEUTICALS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; NATRIURETIC FACTOR; URODILATIN; VASOACTIVE INTESTINAL POLYPEPTIDE;

ACUTE KIDNEY FAILURE; ASTHMA; BLOOD; BRONCHODILATATION; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; HUMAN; NONHUMAN; SECOND MESSENGER; VASODILATATION;

EID: 0030481082     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1996.tb17503.x     Document Type: Conference Paper

References (104)

1. MUTT, V. & S. I. SAID. 1974. Structure of the porcine vasoactive intestinal octacosapeptide. The amino-acid sequence. Use of kallikrein in its determination. Eur. J. Biochem. 42: 581-589.
2. SAID, S. I. & V. MUTT. 1972. Isolation from porcine-intestinal wall of a vasoactive octacosapeptide related to secretin and to glucagon. Eur. J. Biochem. 28: 199-204.
3. SATA, T., J. LINDEN, L. W. LIU, E. KUBOTA & S. I. SAID. 1988. Vasoactive intestinal peptide evokes endothelium-dependent relaxation and cyclic AMP accumulation in rat aorta. Peptides 9: 853-858.
4. DE NEEF, P., P. ROBBERECHT, P. CHATELAIN, M. WAELBROECK & J. CHRISTOPHE. 1984. The in vitro chronotropic and inotropic effects of vasoactive intestinal peptide (VIP) on the atria and ventricular papillary muscle from Cynomolgus monkey heart. Regul. Pept. 8: 237-244.
5. DEY, R. D., W. A. SHANNON & S. I. SAID. 1981. Localization of VIP-immunoreactive nerves in airways and pulmonary vessels of dogs, cats, and human subjects. Cell. Tissue Res. 220: 231-238.
6. FORSSMANN, W.-G., C. TRIPEL, C. DAFFNER & C. H. HEYM. 1986. Vasoactive intestinal peptide in the heart. Ann. N.Y. Acad. Sci. 527: 405.
7. MIYATA, A., A. ARIMURA, R. R. DAHL, N. MINAMINO, A. UEHARA, L. J. IANG, M. D. CULLER & D. H. COY. 1989. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem. Biophys. Res. Commun. 164: 567-574.
8. MIYATA, A., L. J. IANG, R. D. DAHL, C. KITADA, K. KUBO, M. FUJINO, N. MINAMINO & A. ARIMURA. 1990. Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). Biochem. Biophys. Res. Commun. 170: 643-648.
9. KIMURA, C., S. OHKUBO, K. OGI, M. HOSOYA, Y. ITOH, H. ONDA, A. MIYATA, L. J. IANG, R. R. DAHL, H. H. STIBBS, A. ARIMURA & M. FUJINO. 1990. A novel peptide which stimulates adenylate cyclase: Molecular cloning and characterization of the ovine and human cDNAs. Biochem. Biophys. Res. Commun. 166: 81-89.
10. CAUVIN, A., L. BUSCAIL, P. GOURLET, P. DE NEEF, D. GOSSEN, A. ARLMURA, A. MIYATA, D. H. COY, P. ROBBERECHT & J. CHRISTOPHE. 1990. The novel VIP-like hypothalamic polypeptide PACAP interacts with high affinity receptors in the human neuroblastoma .cell line NB-OK. Peptides 11: 773-777.
11. GOTTSCHALL, P. E., I. TATSUNO, A. MIYATA & A. ARIMURA. 1990. Characterization and distribution of binding sites for the hypothalamic peptide, pituitary adenylate cyclase-activating polypeptide. Endocrinology 127: 272-277.
12. GOTTSCHALL, P. E., I. TATSUNO & A. ARIMURA. 1991. Hypothalamic binding sites for pituitary adenylate cyclase activating polypeptide: Characterization and molecular identification. FASEB J. 5: 194-199.
13. ROBBERECHT, P., M. WAELBROECK, P. DE NEEF, J. C. CAMUS, D. H. COY & J. CHRISTOPHE. 1988. Pharmacological characterization of VIP receptors in human lung membranes. Peptides 9: 339-345.
14. ROBBERECHT, P., M. C. WOUSSEN COLLE, P. DE NEEF, P. GOURLET, L. BUSCAIL, A. VANDERMEERS, M. C. VANDERMEERS PIRET & J. CHRISTOPHE. 1991. The two forms of the pituitary adenylate cyclase activating polypeptide (PACAP (1-27) and PACAP (1-38)) interact with distinct receptors on rat pancreatic AR 4-2J cell membranes. FEBS Lett. 286: 133-136.
15. ROBBERECHT, P., P. GOURLET, A. CAUVIN, L. BUSCAIL, P. DE NEEF, A. ARIMURA & J. CHRISTOPHE. 1991. PACAP and VIP receptors in rat liver membranes. Am. J. Physiol. 260: G97-G102.
16. SHIVERS, B. D., T. J. GORCS, P. E. GOTTSCHALL & A. ARIMURA. 1991. Two high affinity binding sites for pituitary adenylate cyclase-activating polypeptide have different tissue distributions. Endocrinology 128: 3055-3065.
17. SAWANGJAROEN, K., C. R. DALLEMAGNE, R. B. CROSS & J. D. CURLEWIS. 1992. Effects of pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal polypeptide (VIP) on the cardiovascular system in sheep. Peptides 13: 1029-1032.
18. ISHIZUKA, Y., K. KASHIMOTO, T. MOCHIZUKI, K. SATO, K. OHSHIMA & N. YANAIHARA. 1992. Cardiovascular and respiratory actions of pituitary adenylate cyclase-activating polypeptides. Regul. Pept. 40: 29-39.
19. MINKES, R. K., T. J. MCMAHON, T. R. HIGUERA, W. A. MURPHY, D. H. COY & P. J. KADOWITZ. 1992. Analysis of systemic and pulmonary vascular responses to PACAP and VIP: role of adrenal catecholamines. Am. J. Physiol. 263: H1659-H1669.
20. FRANCO CERECEDA, A., L. BENGTSSOM & J. M. LUNDBERG. 1987. Inotropic effects of calcitonin gene-related peptide, vasoactive intestinal polypeptide and somatostatin on the human right atrium in vitro. Eur. J. Pharmacol. 134: 69-76.
21. CULLER, M. D. & C. S. PASCHALL. 1991. Pituitary adenylate cyclase-activating polypeptide (PACAP) potentiates the gonadotropin-releasing activity of luteinizing hormone-releasing hormone. Endocrinology 129: 2260-2262.
22. TATSUNO, I., A. SOMOGYVARI VIGH, K. MIZUNO, P. E. GOTTSCHALL, H. HIDAKA & A. ARLMURA. 1991. Neuropeptide regulation of interleukin-6 production from the pituitary: Stimulation by pituitary adenylate cyclase activating polypeptide and calcitonin gene-related peptide. Endocrinology 129: 1797-1804.
23. UDDMAN, R., A. Lurs, A. ARLMURA & F. SUNDLER. 1991. Pituitary adenylate cyclase-activating peptide (PACAP), a new vasoactive intestinal peptide (VIP)-like peptide in the respiratory tract. Cell Tissue Res. 265: 197-201.
24. BRENNER, B. M., B. J. BALLERMANN, M. E. GUNNING & M. L. ZEIDEL. 1990. Diverse biological actions of atrial natriuretic peptide. Physiol. Rev. 70: 665-699.
25. FORSSMANN, W. G. 1986. Cardiac hormones. I. Review on the morphology, biochemistry, and molecular biology of the endocrine heart. Eur. J. Clin. Invest. 16: 439-451.
26. ROSENZWEIG, A. & C. E. SEIDMAN. 1991. Atrial natriuretic factor and related peptide hormones. Annu. Rev. Biochem. 60: 229-255.
27. SONNENBERG, H., U. HONRATH, C. K. CHONG & D. R. WILSON. 1986. Atrial natriuretic factor inhibits sodium transport in medullary collecting duct. Am. J. Physiol. 250: F963-F966.
28. FLYNN, T. G., M. L. DEBOLD & A. J. DEBOLD. 1983. The amino acid sequence of an atrial peptide with potent diuretic and natriuretic properties. Biochem. Biophys. Res. Commun. 117: 859-865.
29. DEBOLD, A. J., H. B. BORENSTEIN, A. T. VERESS & H. SONNENBERG. 1981. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 28: 89-94.
30. FORSSMANN, W. G., D. HOCK, F. LOTTSPEICH, A. HENSCHEN, V. KREVE, M. CHRISTMANN, M. REINECKE, J. METZ, M. CARLQUIST & V. MUTT. 1983. The right auricle of the heart is an endocrine organ. Anat. Embryol. 168: 307-313.
31. KANGAWA, K. & H. MATSUO. 1984. Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (alpha-hANP). Biochem. Biophys. Res. Commun. 118: 131-139.
32. FORSSMANN, W. G., K. NOKIHARA, M. GAGELMANN, D. HOCK, S. M. FELLER, P. SCHULZ-KNAPPE & F. HERBST. 1989. The heart is the center of a new endocrine, paracrine and neuroendocrine system. Arch. Histol. Cytol. 52: 293-315.
33. SUDOH, T., K. KANGAWA, N. MINAMINO & H. MATSUO. 1988. A new natriuretic peptide in porcine brain. Nature 332: 78-81.
34. SUDOH, T., N. MINAMINO, K. KANGAWA & H. MATSUO. 1990. C-type natriuretic peptide (CNP): A new member of natriuretic peptide family identified in porcine brain. Biochem. Biophys. Res. Commun. 168: 863-870.
35. CURRIE, M. G., D. M. GELLER, B. R. COLE, J. G. BOYLAN, W. YUSHENG, S. W. HOLMBERG & P. NEEDLEMAN. 1983. Bioactive cardiac substances: Potent vasorelaxant activity in mammalian atria. Science 221: 71-73.
36. GRAMMER, R. T., H. FUKUMI, T. INAGAMI & K. S. MISONO. 1983. Rat atrial natriuretic factor: Purification and vasorelaxant activity. Biochem. Biophys. Res. Commun. 116: 696-703.
37. GOETZ, K. L. 1988. Physiology and pathophysiology of the atrial peptides. Am. J. Physiol. 254: E1-E15.
38. SCHULZ-KNAPPE, P., K. FORSSMANN, F. HERBST, D. HOCK, R. PIPKORN & W. G. FORSSMANN. 1988. Isolation and structural analysis of "urodilatin," a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine. Klin. Wochenschr. 66: 752-759.
39. FORSSMANN, W. G., M. MEYER & P. SCHULZ-KNAPPE. 1994. Urodilatin: From cardiac hormones to clinical trials. Exp. Nephrol. 2: 318-323.
40. KIRCHHOFF, K., A. BUB, P. MARXEN & W. G. FORSSMANN. 1994. Urodilatin inhibits sodium reabsorption in the isolated perfused rat kidney. Exp. Nephrol. 2: 351-357.
41. DRUMMER, C., F. FIEDLER, A. BUB, D. KLEEFELD, E. DIMITRIADES, R. GERZER & W. G. FORSSMANN. 1993. Development and application of a urodilatin (CDD/ANP-95-126)-specific radioimmunoassay. Pflugers Arch. 423: 372-377.
42. FLÜGE, T., H. FABEL, T. O. WAGNER & W. G. FORSSMANN. 1994. Localization of the bronchodilator effect induced by type A natriuretic peptide in asthmatic subjects. Clin. Investig. 72: 772-774.
43. FLÜGE, T., H. G. HOYMANN, J. HOHLFELD, U. HEINRICH, H. FABEL, T. O. WAGNER & W. G. FORSSMANN. 1994. Type A natriuretic peptides exhibit different bronchoprotective effects in rats. Eur. J. Pharmacol. 271: 395-402.
44. SAID, S. I. 1984. Vasoactive intestinal polypeptide (VIP): Current status. Peptides 5: 143-150.
45. BERISHA, H. I., H. PAKBAZ, S. LYUBSKY & S. I. SAID. 1995. Acute lung injury due to Cobra venom factor in vivo is prevented by vasoactive intestinal peptide (VIP). Am. J. Respir. Crit. Care Med. 151 (4): A767.
46. PAKBAZ, H., H. I. BERISHA, A. ABSOOD, H. D. FODA & S. I. SAID. 1995. Vasoactive intestinal peptide (VIP) as a modulator of neurogenic inflammation in airways. Am. J. Respir. Crit. Care Med. 151 (4): A702.
47. MARUNO, K. & S. I. SAID. 1995. Mechanism of inhibition of human airway smooth muscle (ASM) cell proliferation by vasoactive intestinal peptide (VIP): Role of cyclic AMP protein kinase. Am. J. Respir. Crit. Care Med. 151 (4):A654.
48. MARUNO, K. & S. I. SAID. 1995. Human non-small cell lung carcinoma (NSCLC): Inhibition of proliferation by vasoactive intestinal peptide (VIP). Am. J. Respir. Crit. Care Med. 151(4):A211.
49. KANE, M. G., T. M. O'DORISIO & G. J. KREJS. 1983. Production of secretory diarrhea by intravenous infusion of vasoactive intestinal polypeptide. New Eng. J. Med. 309: 1482-1485.
50. MORICE, A., R. J. UNWIN & P. S. SEVER. 1983. Vasoactive intestinal peptide causes bronchodilatation and protects against histamine-induced bronchoconstriction in asthmatic subjects. Lancet 2: 1225-1227.
51. MORICE, A., R. UNWIN & P. SEVER. 1984. VIP as bronchodilator [Letter]. Lancet 1: 457-458.
52. MORICE, A. H., R. J. UNWIN & P. S. SEVER. 1984. In vivo bronchodilator activity of vasoactive intestinal peptide in the cat (Lett.). Am. J. Respir. Dis. 129: 882.
53. SUZUKI, Y., K. KASAI, K. TAKEKOSHI, M. OKA, N. BANBA, T. NUMAO, H. SUGLMURA, M. IIZUKA & S. SHIMODA. 1993. Effects of pituitary adenylate cyclase activating polypeptide (PACAP) on the cardiovascular system. Regul. Pept. 47: 213-220.
54. ARAKI, N. & K. TAKAGI. 1992. Relaxant effect of pituitary adenylate cyclase-activating polypeptide on guinea-pig tracheal smooth muscle. Eur. J. Pharmacol. 216: 113-117.
55. COX, H. M. 1992. Pituitary adenylate cyclase activating polypeptides, PACAP-27 and PACAP-38: stimulators of electrogenic ion secretion in the rat small intestine. Br. J. Pharmacol. 106: 498-502.
56. WARREN, J. B., J. R. COCKCROFT, S. W. LARKIN, R. KAJEKAR, A. MACRAE, M. A. GHATEI & S. R. BLOOM. 1992. Pituitary adenylate cyclase activating polypeptide is a potent vasodilator in humans. J. Cardiovasc. Pharmacol. 20: 83-87.
57. CHINKERS, M., D. L. GARBERS, M. S. CHANG, D. G. LOWE, H. CHIN, D. V. GOEDDEL & S. SCHULZ. 1989. A membrane form of guanylate cyclase is an atrial natriuretic peptide receptor. Nature (London) 338: 78-83.
58. HELM, J. M., S. KIEFERSAUER, H. J. FÜLLE & R. GERZER. 1989. Urodilatin and β-ANF: Binding properties and activation of paniculate guanylate cyclase. Biochem. Biophys. Res. Commun. 163: 37-41.
59. LOWE, D. G., M. S. CHANG, R. HELLMISS, E. CHEN, S. SINGH, D. L. GARBERS & D. V. GOEDDEL. 1989. Human atrial natriuretic peptide receptor defines a new paradigm for second messenger signal transduction. EMBO J. 8: 1377-1384.
60. KOIKE, J., H. NONOGUCHI, Y. TERADA, K. TOMITA & F. MARUMO. 1993. Effect of urodilatin on cGMP accumulation in the kidney. J. Am. Soc. Nephrol. 3: 1705-1709.
61. MAACK, T. 1992. Receptors of atrial natriuretic factor. Annu. Rev. Physiol. 54: 11-27.
62. KOLLER, K. J. & G. V. GOEDDEL. 1992. Molecular biology of the natriuretic peptides and their receptors. Circulation 86: 1081-1084.
63. CROZIER, I. G., M. G. NICHOLLS, H. IKRAM, E. A. ESPINER, T. G. YANDLE & S. J. ANS. 1986. Atrial natriuretic peptides in humans, production and clearance by various tissues. Hypertension 8 [Suppl.II]:II11-II15.
64. ESPINER, E. A., M. G. NICHOLLS, T. G. YANDLE, I. G. CROZIER, R. C. CUNEO, D. MCCORMICK & H. IKRAM. 1986. Studies on the secretion, metabolism, and action of atrial natriuretic peptide in man. J. Hypertension [Suppl. II]: 85-91.
65. HOLLISTER, A. S., R. J. RODEHEFFER, F. J. WHITE, J. R. POTTS, T. IMADA & T. INAGAMI. 1989. Clearance of atrial natriuretic factor by lung, liver, and kidney in human subjects and the dog. J. Clin. Invest. 83: 623-628.
66. PERRELLA, M. A., K. B. MARGULIES, W. CHI-MING, L. L. AARHUS, D. M. HEUBLEIN & J. C. BURNETT. 1991. Pulmonary and urinary clearance of atrial natriuretic factor in acute congestive heart failure in dogs. J. Clin. Invest. 87: 1649-1655.
67. GAGELMANN, M., D. HOCK & W. G. FORSSMANN. 1988. Urodilatin (CDD/ANP-95-126) is not biologically inactivated by a peptidase from dog kidney cortex membranes in contrast to atrial natriuretic peptide/cardiodilatin (alpha-hANP/CDD-99-126). FEBS Lett. 233: 249-254.
68. KENNY, A. J., A. BOURNE & J. INGRAM. 1993. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem. J. 291: 83-88.
69. OLINS, G. M., K. L. SPEAR, N. R. SIEGEL & H. A. ZURCHERNEELY. 1987. Inactivation of atrial natriuretic factor by the renal brush border. Biochem. Biophys. Acta 901: 97-100.
70. STEPHENSON, S. L. & A. J. KENNY. 1987. The hydrolysis of alpha-human atrial natriuretic peptide by pig kidney microvillar membranes is initiated by endopeptidase-24.11. Biochem. J. 243: 183-187.
71. FELLER, S. M., A. BUB, M. GAGELMANN & W. G. FORSSMANN. 1991. Natriuretic peptides from the heart, brain, and kidney: Localization, processing, vasoactivity, and proteolytic degradation. In Heart Failure Mechanisms and Management, B. S. Lewis and A. Kimchi, Eds.: 398-407. Springer-Verlag. Berlin-Heidelberg.
72. GOETZ, K., C. DRUMMER, J. L. ZHU, R. LEADLEY, F. FIEDLER & R. GERZER. 1990. Evidence that urodilatin, rather than ANP, regulates renal sodium excretion. J. Am. Soc. Nephrol. 1: 867-874.
73. DRUMMER, C., F. FIEDLER, A. KONIG & R. GERZER. 1991. Urodilatin, a kidney-derived natriuretic factor, is excreted with a circadian rhythm and is stimulated by saline infusion in man. J. Am. Soc. Nephrol. 1: 1109-1113.
74. EMMELUTH, C., C. DRUMMER, R. GERZER & P. BIE. 1992. Roles of cephalic Na+ concentration and urodilatin in control of renal Na+ excretion. Am. J. Physiol. 262: F513-F516.
75. MEYER, M., R. RICHTER, R. BRUNKHORST, E. WRENGER, P. SCHULZ-KNAPPE, A. KIST, P. MENTZ, E. G. BRABANT, K. M. KOCH, G. RECHKEMMER & W. G. FORSSMANN. 1996. Urodilatin is involved in sodium homeostasis and exerts sodium-state-dependent natriuretic and diuretic effects. Am. J. Physiol. 271:: F489-F497.
76. DRUMMER, C., R. GERZER, M. HEER, B. MOLZ, P. BIE, M. SCHLOSSBERGER, C. STADAEGER, L. RÖCKER, F. STROLLO, B. HEYDUCK, K. BAUER, J. WARBERG, F. BAISCH, N. J. CHRISTENSEN, A. KÖNIG & P. NORSK. 1993. Effects of an acute saline infusion on fluid and electrolyte metabolism in humans. Am. J. Physiol. 262: F744-F754.
77. GOETZ, K. L. 1993. Is urodilatin (rather than atriopeptin) the primary natriuretic peptide of the ANP family? J. Cardiovasc. Pharmacol. 22 (Suppl. 2):S84-S85.
78. FIGUEROA, C. D., H. M. LEWIS, A. G. MACIVER, J. C. MACKENZIE & K. D. BHOOLA. 1990. Cellular localisation of atrial natriuretic factor in the human kidney. Nephrol. Dial. Transplant. 5: 25-31.
79. SCHULZ-KNAPPE, P., U. HONRATH, W. G. FORSSMANN & H. SONNENBERG. 1990. Endogenous natriuretic peptides: Effect on collecting duct function in rat kidney. Am. J. Physiol. 259: F415-F418.
80. RIEGGER, G. A. J., D. ELSNER, W. G. FORSSMANN & E. P. KROMER. 1990. Effects of ANP-(95-126) in dogs before and after induction of heart failure. Am. J. Physiol. 259: H1643-H1648.
81. SAXENHOFER, H., A. RASELLI, P. WEIDMANN, W. G. FORSSMANN, A. BUB, P. FERRARI & S. G. SHAW. 1990. Urodilatin, a natriuretic factor from kidneys, can modify renal and cardiovascular function in men. Am. J. Physiol. 259: F832-F838.
82. RIEGGER, G. A., D. ELSNER, E. P. KROMER, C. DAFFNER, W. G. FORSSMANN, F. MUDERS, E. W. PASCHER & K. KOCHSIEK. 1988. Atrial natriuretic peptide in congestive heart failure in the dog: Plasma levels, cyclic guanosine monophosphate, ultrastructure of atrial myoendocrine cells, and hemodynamic, hormonal, and renal effects. Circulation 77: 398-406.
83. VILLARREAL, D., R. H. FREEMAN & R. A. JOHNSON. 1991. Renal effects of ANF (95-126), a new atrial peptide analogue, in dogs with experimental heart failure. Am. J. Hypertens. 4: 508-515.
84. KENTSCH, M., D. LUDWIG, C. DRUMMER, R. GERZER & G. MULLER ESCH. 1992. Haemodynamic and renal effects of urodilatin in healthy volunteers. Eur. J. Clin. Invest. 22: 319-325.
85. KENTSCH, M., D. LUDWIG, C. DRUMMER, R. GERZER & G. MULLER ESCH. 1992. Haemodynamic and renal effects of urodilatin bolus injections in patients with congestive heart failure. Eur. J. Clin. Invest. 22: 662-669.
86. GREENBERG, A., J. W. EGEL, M. E. THOMPSON, R. L. HARDESTY, B. P. GRIFFITH, H. T. BAHNSON, R. L. BERNSTEIN, A. HASTILLO, M. L. HESS & J. B. PUSCHETT. 1987. Early and late forms of cyclosporine nephrotoxicity: Studies in cardiac transplant recipients. Am. J. Kidney Dis. 9: 12-22.
87. MCGRIFFITH, D. C., J. K. KIRKLIN & D. C. NAFTEL. 1985. Acute renal failure following cardiac transplantation with cyclosporine. Heart Transplant. 4: 396-399.
88. MASON, J. 1990. The pathophysiology of Sandimmune (cyclosporine) in man and animals. Pediatr. Nephrol. 4: 686-704.
89. KLEINERT, H. D., T. MAACK, S. A. ATLAS, A. J. ANUSZEWICZ, J. E. SEALEY & J. H. LARAGH. 1984. Atrial natriuretic factor inhibits angiotensin-, norepinephrine-, and potassium-induced vascular contractility. Hypertension 6: I143-I147.
90. SCHRAMM, L., E. HEIDBREDER, J. SCHAAR, K. LOPAU, J. ZIMMERMANN, R. GÖTZ, H. LING & A. HEIDLAND. 1994. Toxic acute renal failure in the rat: Effects of Diltiazem and Urodilatin on renal function. Nephron 68: 454-461.
91. HUMMEL, M., M. KÜHN, A. BUB, H. BITTNER, D. KLEEFELD, P. MARXEN, B. SCHNEIDER, R. HETZER & W. G. FORSSMANN. 1992. Urodilatin: A new peptide with beneficial effects in the postoperative therapy of cardiac transplant recipients. Clin. Invest. 70: 674-682.
92. LANGREHR, J. M., A. KAHL, M. MEYERS, U. NEUMANN, M. KNOOP, S. JONAS, W.-O. BECHSTEIN, U. FREI, W.-G. FORSSMANN & P. NEUHAUS. Prophylactic use of low-dose urodialtin following liver transplantation: A randomized placebo-controlled study. Submitted to Clin. Transplantation.
93. BRENNER, P., M. MEYER, H. REICHENSPURNER, B. MEISER, R. MÜLLER, P. MENTZ, P. SCHULZ-KNAPPE, H. J. ÜBERBACHER, E. KREUZER, P. ÜBERFÜHR, W. G. GUDER, H. WENZLAFF, H. TESCHEMACHER, B. REICHART & W.-G. FORSSMANN. 1995. Significance of prophylactic Urodilatin (INN: Ularitide) infusion for prevention of acute renal failure in patients after heart transplantation. Eur. J. Med. Res. 1: 137-143.
94. CEDIDI, C., M. MEYER, E. R. KUSE, P. SCHULZ-KNAPPE, B. RINGE, U. FREI, R. PICHLMAYR & W. G. FORSSMANN. 1994. Urodilatin: A new approach for the treatment of therapy-resistant acute renal failure after liver transplantation. Eur. J. Clin. Invest. 24: 632-639.
95. KUSE, E.-R., M. MEYER, R. CONSTANTIN, K. OLDHAFER, H.-J. SCHLITT, P. SCHULZ-KNAPPE, H.-J. ÜBERBACHER, R. PICHLMAYR & W.-G. FORSSMANN. 1996. Urodilatin (INN: Ularitide) - A novel peptide for the treatment of postoperative acute renal failure following liver transplantation. Anaesthesist 45: 351-358.
96. WIEBE, K., M. MEYER, T. WAHLERS, D. ZENKER, F.-P. SCHULZE, P. MICHELS, H. DALICHAU, F. W. MOHR, H.-G. BORST & W.-G. FORSSMANN. 1996. Acute renal failure following cardiac surgery is reverted by administration of Urodilatin (INN: Ularitide). Eur. J. Med. Res. 1: 1-7.
97. MEYER, M. W. BRETT, P. MENTZ, A. KIST, P. SCHULZ-KNAPPE, R. RICHTER, R. BRUNK-HORST, H.-J. ÜBERBACHER, K. WIEBE, T. WAHLERS, M. WIESSNER, D. ZENKER, F.-P. SCHULZE, W. FRETER, H. DALICHAU, F. W. MOHR & W.-G. FORSSMANN. 1966. Treatment of acute renal failure in 38 patients with Urodilatin (INN: Ularitide) as "compassionate use" after liver transplantation and cardiac surgery. Eur. J. Clin. Invest. Submitted.
98. LAWS, J., S. KROPP, M. MEYER, W.-G. FORSSMANN & S. BURDACH. 1995. Treatment of acute renal failure with Urodilatin after unrelated bone marrow transplantation in an 18-month-old boy. Bone Marrow Transplant. 16: 307-310.
99. MORICE, A. H. & P. S. SEVER. 1986. Vasoactive intestinal peptide as a bronchodilator in severe asthma. Peptides 7(Suppl. 1):279-280.
100. HULKS, G., A. JARDINE, J. M. CONNELL & N. C. THOMSON. 1989. Bronchodilator effect of atrial natriuretic peptide in asthma. Br. Med. J. 299: 1081-1082.
101. CARDELL, L. O., R. UDDMAN, A. LUTS & F. SUNDLER. 1991. Pituitary adenylate cyclase activating peptide (PACAP) in guinea-pig lung: Distribution and dilatory effects. Regul. Pept. 36: 379-390.
102. FLÜGE, T., H. FABEL, T. O. F. WAGNER, B. SCHNEIDER & W.-G. FORSSMANN. 1995. Urodilatin (Ularitide, INN): A potent bronchodilator in asthmatic subjects. Eur. J. Clin. Invest. 25: 728-736.
103. FLÜGE, T., H. FABEL, T. O. F. WAGNER, B. SCHNEIDER & W.-G. FORSSMANN. 1995. Bronchodilating effects of natriuretic and vasorelaxant peptides compared to salbutamol in asthmatics. Regul. Pept. 59: 357-370.
104. ELSNER, D., F. MUDERS, A. MUNTZE, E. P. KROMER, W. G. FORSSMANN & G. A. RIEGGER. 1995. Efficacy of prolonged infusion of urodilatin [ANP-(95-126)] in patients with congestive heart failure. Am. Heart J. 129: 766-773.